103 related articles for article (PubMed ID: 21382413)
1. Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Manosuthi W; Lueangniyomkul A; Mankatitham W; Chimsuntorn S; Tantanathip P; Thongyen S; Suntisuklappon B; Nilkamhang S; Sungkanuparph S
J Infect; 2011 May; 62(5):406-9. PubMed ID: 21382413
[No Abstract] [Full Text] [Related]
2. The art of managing human immunodeficiency virus infection: a balancing act.
Reiss P
Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
[No Abstract] [Full Text] [Related]
3. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of renal impairment observed in tenofovir-treated patients.
O'Donnell EP; Scarsi KK; Darin KM; Gerzenshtein L; Postelnick MJ; Palella FJ
J Antimicrob Chemother; 2011 May; 66(5):1120-6. PubMed ID: 21393145
[TBL] [Abstract][Full Text] [Related]
5. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Manfredi R
Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
[No Abstract] [Full Text] [Related]
6. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
[TBL] [Abstract][Full Text] [Related]
7. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
8. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Menezes CN; Crowther NJ; Duarte R; Van Amsterdam D; Evans D; Dickens C; Dix-Peek T; Rassool M; Prinsloo A; Raal F; Sanne I
HIV Med; 2014 Jan; 15(1):3-12. PubMed ID: 23980620
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Smith DE; Chan DJ; Maruszak H; Jeganathan S
Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
[TBL] [Abstract][Full Text] [Related]
11. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
[No Abstract] [Full Text] [Related]
12. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
13. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
14. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
[TBL] [Abstract][Full Text] [Related]
15. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir regimen compared with Combivir.
AIDS Patient Care STDS; 2005 Jan; 19(1):59-60. PubMed ID: 15700398
[No Abstract] [Full Text] [Related]
17. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Cournil A; Coudray M; Kouanfack C; Essomba CN; Tonfack CA; Biwolé-Sida M; Delaporte E; Bork K; Laurent C
Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV agents. Merck integrase inhibitor.
TreatmentUpdate; 2006; 18(4):3-4. PubMed ID: 17205652
[No Abstract] [Full Text] [Related]
19. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
[TBL] [Abstract][Full Text] [Related]
20. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Winston A; McAllister J; Amin J; Cooper DA; Carr A
HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]